
TEM Stock Forecast & Price Target
TEM Analyst Ratings
Bulls say
Tempus AI is well-positioned in the healthcare technology space with its unique Tempus Platform that utilizes AI to make laboratory tests more accurate and personalized. The recent FDA clearance for its ECG-PH software adds to its growing portfolio of FDA-cleared products, increasing its addressable market and reinforcing the scalability of its AI platform. With a projected sales per share of $9.87 and a net debt of $3.00 per share, we have a positive outlook for the company with a 12-month price target of $76. Risks to our outlook include lower than projected sales growth and potential dilution risk, but we believe the company's acquisition of Personalis and its role in individualized mRNA therapies, as well as its expansion into MRD coverage and data licensing, position it for strong growth and potential future partnerships.
Bears say
Tempus AI is acquiring Personalis, a move that is expected to improve the quality of the asset without changing the agreed upon consideration. With a mechanical proforma LTM EV/Revenue multiple of 8.9x, or 7.0x forward EV/Revenue multiple, and potential for premium due to successful integration, MRD adoption, and increased biopharma demand, the update is viewed as strategically positive. However, there may be reimbursement risks with Medicare coverage not guaranteeing commercial payer follow-on.
This aggregate rating is based on analysts' research of Tempus AI Inc and is not a guaranteed prediction by Public.com or investment advice.
TEM Analyst Forecast & Price Prediction
Start investing in TEM
Order type
Buy in
Order amount
Est. shares
0 shares